OligoCare Research Opportunities: Partners and researchers within the OligoCare community now have the opportunity to propose and evaluate ideas with the steering committee, opening doors to exciting research prospects.

Patient Enrolment Milestone: The OligoCare community celebrated the recruitment of over 2500 patients, expressing gratitude for the collective effort driving crucial research forward.

Tailoring Treatments for Personalized Care: Emphasis on different biological doses based on tumour type and site underscored the importance of personalized care in the treatment of oligometastatic disease.

Safety as a Top Priority: The symposium reiterated the commitment to safety, with minimal toxicity and complications leading to SBRT-related deaths, emphasizing the paramount importance of patient safety.

Prostate Cancer Quality of Life (QoL): Insights revealed that QoL in prostate cancer patients remains stable during the initial 6 months of SBRT for Oligometastatic Disease, empowering patients on their cancer journey.

Holistic Patient Well-being: Baseline QoL comparability across tumour types emphasized the need for holistic approaches, addressing the overall well-being of patients undergoing treatment.

ARTO Trial Breakthroughs: The ARTO trial showcased significant advancements with improved biochemical response, progression-free survival (PFS), and time to the next systemic treatment in mCRPC OMD cases.

STOP Trial Insights: Results from the STOP trial clarified that standard of care (SOC) + SBRT and SBRT yield similar median PFS for oligoprogressive cancer, guiding clinicians in treatment decisions.

CURB Trial Impact: The CURB trial demonstrated increased PFS with SBRT + standard care, particularly in breast cancer cases, laying the groundwork for future advancements in cancer treatment.

SABR Insights for Lung Disease: Exploring SABR for OMD lung disease, the symposium revealed that single vs. multifraction SABR showed no significant impact on results, providing valuable insights for better decision-making in lung cancer treatment.